Fed Circuit: ‘Safe Harbor’ Provision Is Broad: Amphastar, Momenta Dispute

Generic Line
A 2–1 final federal appeals court decision that lifts an injunction barring Watson Pharmaceuticals and Amphastar from selling a generic version of Sanofi’s blockbuster blood-thinner Lovenox hinged on an expansive interpretation of Hatch-Waxman’s “safe harbor” provision — a move that could have wide-ranging implications for all patent holders, warns Momenta Pharmaceuticals, which lost its appeal.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00